Abstract:Importance: Incidence rates for lower extremity deep vein thrombosis (DVT) range from 88 to 112 per 100 000 person-years and increase with age. Rates of recurrent VTE range from 20% to 36% during the 10 years after an initial event. Observations: PubMed and Cochrane databases were searched for English-language studies published from January 2015 through June 2020 for randomized clinical trials, meta-analyses, systematic reviews, and observational studies. Risk factors for venous thromboembolism (VTE), such as older age, malignancy (cumulative incidence of 7.4% after a median of 19 months), inflammatory disorders (VTE risk is 4.7% in patients with rheumatoid arthritis and 2.5% in those without), and inherited thrombophilia (factor V Leiden carriers with a 10-year cumulative incidence of 10.9%), are associated with higher risk of VTE. Patients with signs or symptoms of lower extremity DVT, such as swelling (71%) or a cramping or pulling discomfort in the thigh or calf (53%), should undergo assessment of pretest probability followed by D-dimer testing and imaging with venous ultrasonography. A normal D-dimer level (ie, D-dimer <500 ng/mL) excludes acute VTE when combined with a low pretest probability (ie, Wells DVT score ≤1). In patients with a high pretest probability, the negative predictive value of a D-dimer less than 500 ng/mL is 92%. Consequently, D-dimer cannot be used to exclude DVT without an assessment of pretest probability. Postthrombotic syndrome, defined as persistent symptoms, signs of chronic venous insufficiency, or both, occurs in 25% to 50% of patients 3 to 6 months after DVT diagnosis. Catheter-directed fibrinolysis with or without mechanical thrombectomy is appropriate in those with iliofemoral obstruction, severe symptoms, and a low risk of bleeding. The efficacy of direct oral anticoagulants-rivaroxaban, apixaban, dabigatran, and edoxaban-is noninferior to warfarin (absolute rate of recurrent VTE or VTE-related death, 2.0% vs 2.2%). Major bleeding occurs in 1.1% of patients treated with direct oral anticoagulants vs 1.8% treated with warfarin. Conclusions and relevance: Greater recognition of VTE risk factors and advances in anticoagulation have facilitated the clinical evaluation and treatment of patients with DVT. Direct oral anticoagulants are noninferior to warfarin with regard to efficacy and are associated with lower rates of bleeding, but costs limit use for some patients.

Choice and Duration of Anticoagulation for Venous Thromboembolism

Management of Venous Thromboembolism: A Systematic Review for a Practice Guideline

Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review

Duration of anticoagulation of venous thromboembolism

How I treat the co-occurrence of venous & arterial thromboembolism: Anticoagulation, antiplatelet therapy, or both?

Proper application of anticoagulation therapy on cancer-associated venous thrombosis

Management of lower-extremity venous thromboembolism: An updated review

Pharmacological Thromboprophylaxis for VTE Post-Endovenous Ablation of Varicose Veins: Network Meta-Analysis

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism

Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling

Extended anticoagulation after venous thromboembolism

How to Evaluate and Choose the Proper Treatments for Patients with Lower Extremity Venous Disease

Antithrombotic Therapy after Deep Venous Intervention

Contemporary Treatment of Venous Thromboembolic Disease

Management of venous thromboembolism in patients with active cancer

Venous Thromboembolism Prevention in COVID-19: A Review of Latest Evidences

Current status of treatment of cancer-associated venous thromboembolism

Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants

Influence of clinical presentation, site, and extent of venous thrombosis on decision about duration of anticoagulation: Data from the international, prospective, observational WHITE study

The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice

A Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous Thromboembolism